About Jingjun Huang
Jingjun “Jim” Huang founded Ascendia in 2012 and is its CEO. Ascendia provides formulation, analytical and manufacturing services. He has led oral and injectable dosage forms from discovery through formulation, manufacturing, technical transfer and commercialization. His research focuses on solubility, dissolution and controlled delivery for poorly water-soluble drugs. He has reviewed for several pharmaceutical journals and belongs to AAPS and ACS.
Before founding Ascendia, Huang worked in pharmaceutical research, development and management at Pfizer, Baxter, AstraZeneca and Roche. He holds a doctorate in pharmaceutics from the University of the Sciences in Philadelphia. He is also a director of Ascendia Pharmaceuticals.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Jingjun Huang in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jingjun Huang works with at each company, as listed on that company's latest Form D.
